---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-100709"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2024-09-17T23:59:59+00:00"
generated_at: "2026-05-31T04:09:47.910411+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Traws Pharma approves 1-for-25 reverse stock split, regains Nasdaq equity compliance

## Summary
- Board approved 1-for-25 reverse split; effective Sept 20, trading split-adjusted Sept 23.
- Authorized shares increased from 125M to 250M; stockholders approved conversion of Series C Preferred.
- Director James Marino resigned; Luba Greenwood appointed to board and committees.
- Company believes it now satisfies Nasdaq $2.5M stockholders' equity requirement after conversion; delisting risk remains.
- Annual meeting set for Oct 31, 2024; shareholder proposals due Sept 26, 2024.

## SEC filing metadata
- accession: 0001104659-24-100709
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2024-09-17T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 5.02, 5.03, 5.07, 5.08, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465924100709/0001104659-24-100709-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465924100709/tm2424247d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-100709
- JSON: https://secwatch.observer/filing/0001104659-24-100709.json
- Plain text: https://secwatch.observer/filing/0001104659-24-100709.txt

## Key facts
- Executive change
  James J. Marino resigned as Director at Traws Pharma, Inc..
  - Action: resigned
  - Role: Director
  source text: On September 16, 2024, James J. Marino, a member of the Board of Directors (the “Board”) of Traws Pharma, Inc. (the “Company”), resigned as a director.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1130598/000110465924100709/0001104659-24-100709-index.htm
- Executive change
  Luba Greenwood was appointed as Director at Traws Pharma, Inc..
  - Action: appointed
  - Role: Director
  source text: the Board appointed Luba Greenwood to the Board to fill the vacancy created by Mr. Marino’s resignation with a term expiring at the Company’s 2024 annual meeting of stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1130598/000110465924100709/0001104659-24-100709-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.